23:31 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus; viral infection Cell culture studies suggest two sialylated IGHA1 isotype mAbs targeting HA could help treat influenza and Newcastle disease. The IGHA1 isotype mAbs consist of the variable regions of two previously...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

NDV-3: Phase I data

A double-blind, placebo-controlled Phase I trial in 160 healthy volunteers showed that single doses of intramuscular 300 µg NDV-3 with or without alum adjuvant and single doses of intradermal 30 µg NDV-3 without alum adjuvant...
07:00 , Apr 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal failure Transglutaminase 2 (TGM2; TG2) In vitro and mouse studies suggest inhibiting TG2 could help treat IgA-induced nephropathy. In mice, transgenic overexpression of...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

NDV-3: Phase I data

A double-blind, placebo-controlled Phase I trial in 40 healthy volunteers showed that single doses of 30 and 300 µg NDV-3 resulted in 100% seroconversion of both serum IgG and IgA1 antibodies by day 14, with...